MedTrace Logo

A Community Engagement Approach to Improving Communication With Black Men About Oral and Pharyngeal Cancers

NCT07172776 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-29

No results posted yet for this study

Summary

1. Specific OPC patient communication (COPC) tool to address OPCs among Black men.
2. Assess the COPC tool's ability to improve dental providers' communication with Black men.
3. Implement a pilot test of the culturally tailored OPC communication tool in community-based settings to assess perceptions, knowledge and experiences of Black men receiving oral cancer screenings

Conditions

  • Oral Cancers

Interventions

BEHAVIORAL

oral cancer communication tool

The overall goal is to determine if the OPC communication tool has potential to enhance Black-men's and dentists' comfort discussing oral and pharyngeal cancers in clinical-like settings. Each Aim builds upon activities from the previous Aim. Aim 1a and Aim1b activities will produce a culturally- aligned oral-pharyngeal cancer communication (COPC) tool that will be used in Aim 2. In Aim 2 activities, dental providers will receive training on the tool and practice utilization of the tool. The tool will be further revised using the additional feedback from Aim 2 activities. In Aim 3, the revised culturally- aligned COPC tool will be utilized in community-based settings. In this IRB amendment-modification, we are seeking approval for Phase III/ Aim 3 activities.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-12-31
Completion
2027-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172776 on ClinicalTrials.gov